SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
XFOR

X4 Pharmaceuticals, Inc (NASDAQ:XFOR)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.00+$0.04 (+1.35%)
 
Market cap
$306M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 16, 2017
Market Cap$306.34M-20.0%
Revenue (ttm)$16.96M-50.1%
Net Income-$80.52M+15.3%
EPS-$0.67+93.4%
Shares Out102.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,825,293
Open$2.93
Previous Close$2.96
Day's Range$2.89 - $3.06
52-Week Range$2.43 - $4.83
Beta0.35
AnalystsBuy
Price Target$11.50(+283.33%)
Earnings DateMar 16, 2027

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Address
61 North Beacon Street, Boston, MA, 02134, US
Market Cap
306 million
Employees
45
Industrial Classification
Biotechnology

X4 Pharmaceuticals, Inc Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
3rd Percentile Overall Score
XFOR InsiderScore:30 / 99

X4 Pharmaceuticals, Inc scored higher than 3% of companies evaluated by InsiderBuying, and ranked 95th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at X4 Pharmaceuticals, Inc bought $11.9K of stock across 1 purchase in the last 90 days, the largest of them $11.9K.

Stake Increase

The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$462.91K
Bought
$261.88K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From XFOR’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+1.35%
5 Days
-3.23%
1 Month
-0.33%
6 Months
-25.74%
1 Year
-20.00%

$XFOR stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in XFOR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by XFOR's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

XFOR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

XFOR Revenue by Segment

$1.02MTotal
Balance as of September 30, 2026$567.00K55.32%
Beginning balance at December 31, 2025$458.00K44.68%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New XFOR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to XFOR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in XFOR

VTIVanguard Morningstar Total Stock Market ETF$6.86M
IWMiShares Russell 2000 ETF$6.35M
VXFVanguard Extended Market ETF$2.93M
IWNiShares Russell 2000 Value ETF$2.39M
VTWOVanguard Russell 2000 ETF$1.65M
IWCiShares Micro-Cap ETF$752.94K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from XFOR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
29.71
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
5
Buy Value
$261.88K
Distinct Buyers
1

Insider Score Trend Over Time

+29.7 since Sep 10
0255075100Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 28.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Oct 19 — Insider Score 46.9Oct 20 — Insider Score 46.6Oct 21 — Insider Score 46.5Oct 22 — Insider Score 46.4Oct 23 — Insider Score 46.5Oct 24 — Insider Score 46.4Oct 25 — Insider Score 46.1Oct 26 — Insider Score 46.0Oct 27 — Insider Score 46.1Oct 28 — Insider Score 45.9Oct 29 — Insider Score 45.3Oct 30 — Insider Score 44.2Oct 31 — Insider Score 43.7Nov 1 — Insider Score 43.9Nov 2 — Insider Score 44.0Nov 3 — Insider Score 43.1Nov 4 — Insider Score 42.4Nov 5 — Insider Score 41.8Nov 6 — Insider Score 40.6Nov 7 — Insider Score 40.0Nov 8 — Insider Score 40.6Nov 9 — Insider Score 40.9Nov 10 — Insider Score 39.5Nov 11 — Insider Score 38.5Nov 12 — Insider Score 38.2Nov 13 — Insider Score 36.8Nov 14 — Insider Score 35.7Nov 15 — Insider Score 36.3Nov 16 — Insider Score 35.9Nov 17 — Insider Score 33.8Nov 18 — Insider Score 32.6Nov 19 — Insider Score 31.5Nov 20 — Insider Score 30.0Nov 21 — Insider Score 29.4Nov 22 — Insider Score 29.7Sep 10Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.45%
SBIOALPS Medical Breakthroughs ETF0.20%
IWCiShares Micro-Cap ETF0.07%
FSEVFidelity Enhanced Small Cap Value ETF0.06%

Weight is the stock’s share of each fund’s holdings.